FDA Begins Review of Abortion Pill Mifepristone After GOP Requests

1 DAY AGO·UPDATED 14 HOURS AGO

story

Above: FDA Commissioner Dr. Marty Makary speaks in the Roosevelt Room of the White House on Sept. 22, 2025. Image copyright: Andrew Harnik/Getty Images

The Spin

Republican narrative

The FDA’s decision to review mifepristone is a vital step toward protecting women and unborn children from a drug long misrepresented as safe. Real-world data show over 10% of women suffer serious complications — far above the 0.5% claimed in trials — and at least 36 have died. The abortion industry has downplayed these risks for decades. It’s time to restore strict safety protocols and hold manufacturers accountable for the harm caused by chemical abortions.

National Right to Life EPPC

Democratic narrative

The Trump administration’s mifepristone “review” is a politically driven attack on science and reproductive freedom, built on a single junk report from anti-abortion activists that contradicts over 100 peer-reviewed studies and decades of safe use by 7.5 million Americans. This isn’t about safety — it’s about dismantling telehealth and mail-order access to abortion pills and paving the way for a nationwide ban. Americans deserve evidence-based policy, not propaganda masquerading as science.

Substack Ms. Magazine